



CAPSILEAN™

Fire up Fat Loss

Fat isn't just uncomfortable—it's unhealthy. With the growing obesity epidemic, weight loss is a major focal point in the health care industry. Estimated medical expenses this year alone are nearly \$210 **billion** dollars.

Obesity is deadly.

Failing to lose weight can lead to more serious health issues-and while you're struggling with weight loss, being overweight can cause *low self-esteem*, *depression* and a **reduced quality of life**.

Because of that, many overweight people are *desperate for a solution*. When it comes to weight loss, the source of stubborn fat can be **more than one**. When diet and exercise aren't working, it's an indicator that other problems are to blame.

Organic deficiencies, hormones, aging and gut bacteria can all be part of the problem.

But most solutions out there only address one problem. Until now.

CAPSILEAN™: A Comprehensive Approach to Weight Loss

- Triggers thermogenesis to increase the number of calories you burn every day.
- Reduces carb absorption and blood glucose after eating.
- Increases carb and glucose metabolism to reduce the impact of carbs and sugar on body.
- Reduces fat accumulation and weight.
- Breaks down and burns fat.
- Decreases appetite.
- Improves cholesterol.
- Improves insulin sensitivity.
- Reduces waist hip ratio.
- Prevents muscle breakdown.

- Aids in digestion.
- Improves nutrient absorption.
- Improves overall body composition.


CAPSILEAN™ FORMULA

CAPSILEAN™ attacks weight loss from multiple angles with synergistically paired and scientifically supported ingredients.



OMNILEAN™ Reduces Carb and Fat Absorption

Weight gain starts with what you eat. The way your body absorbs carbohydrates and sugars can have a critical bearing on weight. Omnilean™ is Salacia Chinensis Extract from the root of a plant that is used in weight management and in the prevention of diabetes in ancient Indian medicine.



Omnilean™


- Inhibits Alpha glucosidase which slows down glucose absorption.
- Reduces the impact of carbs and blood sugar on the body.
- Reduces blood glucose levels after eating.
- Reduces carb absorption after eating.
- Increases carb metabolism.
- Increases glucose metabolism.
- Decreases insulin resistance.
- Improves uptake of glucose.
- Reduces fat accumulation.
- Reduces weight.

Omnilean™ acts as an [alpha-glucosidase inhibitor](#). Alpha-glucose inhibition slows down glucose absorption which reduces the effect of carbohydrates on the body.

Sugar and simple carbs, like breads and sweets, are broken down very quickly by the body and converted into glucose. Glucose is released into the blood stream and what is not used for energy is stored as fat for future energy use. Slowing down the absorption of carbohydrates reduces glucose and fat storage. Additionally, Omnilean™ [hydrolyzes](#), or breaks down fat so your body can't store it. So while it's reducing carb absorption, it also takes bad fats and breaks them down so the body doesn't store it on common places like your hips, thighs and gut.

In [studies](#) the test subject, obese mice, lost **14 percent of their body weight in seven weeks when taking SCE**.

OmniLean significantly ↓ body weight in OB mice



Studies showed Omnilean™ reduced fat absorption, glucose, insulin resistance and slowed carb absorption which resulted in weight loss.

Adiponectin	Insulin	Leptin
15.8	-21.0	-20.4
↓ fat absorption ↓ glucose ↓ ↓ insulin resistance ↓ body weight	↑ carbohydrate ↓ ↓ glucose ↓ ↓ body weight	↓ hunger ↓ ↓ energy intake ↓ ↓ body weight

Studies also show Omnilean™ reduced the urge to snack and increased feelings of being satisfied longer by suppressing hunger hormone activity.

What makes it different? OmniActive™ has an internal verification program called “PlantActive” to ensure that every batch of OmniLean™ provides both beneficial levels of active compounds and biologic activity to support healthy carbohydrate and lipid metabolism for weight management.

ENSURING QUALITY AND PERFORMANCE WITH PLANTACTIVE™ VERIFICATION PROGRAM



A multifunctional approach to metabolic health requires a multifunctional approach to formulation. The PlantActive™ Verification program is new from OmniActive as part of our continual efforts to improve the quality and performance of our ingredients. By using a proprietary process to deliver a unique set of fingerprinted bioactives **AND** bioactivity from Salacia, PlantActive™ ensures consistent performance for key parameters of metabolic health.

The Science Behind Salacia Extract


The various active principles of Salacia include:

- Diterpenes
- Friedelanes
- Mangiferin
- Megastigmane glycosides
- Oleananes,
- Polyols
- Quinonemethides
- Thiocyclitol
- Triterpenes

Salacia has been known to control weight and obesity issues. Its effect on obese patients has been extensively studied. In most pertinent part, its role as an alpha-glucosidase inhibitor.

OmniLean™ SCE stem and roots contain alpha-glucosidase inhibitors salacinol and kotalanol. Alpha-glucosidase is an intestinal enzyme. It breaks down sucrose into both glucose and fructose. Alpha-glucosidase inhibitors, also called starch blockers, slow or prevent the absorption of certain carbohydrates in the gastrointestinal tract.


The result delays and reduces the amount of glucose available for absorption by interfering with the breakdown of the long-chain carbohydrates. This allows the pancreas more time to secrete insulin to properly utilize sugar.



Insulin is a hormone made by the pancreas that allows your body to use glucose from carbohydrates in the food that you eat for energy or to store glucose for future use. It regulates blood sugar level so it doesn't get too high or low.

After you eat food and your blood sugar level rises, beta cells in your pancreas release insulin into your blood. Insulin responds and triggers cells to absorb sugar from the blood. Insulin allows sugar to be used by cells for energy.

If you have a surplus of sugar, insulin pilots the storage of sugar in your liver and releases it when your blood sugar is low or increased energy usage demands it.



Insulin response. Public Domain.

In other words, Alpha-glucose inhibition slows down the absorption of glucose which reduces the effect of carbohydrates on the body. Because inhibition of alpha-glucosidase, less glucose is absorbed because the carbs are not broken down into glucose molecules.

Less glucose molecules means less glucose to store and convert into fat.

Because alpha-glucosidase inhibitors prevent the breakdown and digestion of carbohydrates into glucose, the carbs remain in the intestine. Bacteria then consumes and digests them causing some gastrointestinal side effects such as gas.

Studies:


In Omnilean, the salacia composition includes at least 12% of polyphenols, 2% of Mangiferin, and 1% of 25, 26-oxidofriedelane-1,3-dione by weight of the composition in the form of extract.

Studies were conducted with sucrose loading, rather than starch, as recommended by FDA for alpha-glucosidase inhibitor products and sucrose is the most suitable carbohydrate load.


Sucrose loading in testing is more accurate than testing with a meal because it produces a reproducible change in blood glucose concentration. Additionally, as a disaccharide, it cannot be absorbed until it is broken down to glucose and fructose α -glucosidase.

Reduced Postprandial Blood Glucose

After a dose of SCE, the decrease in absorption of glucose produced from sucrose reflects the activity of α -glucosidase, successfully reflecting the efficacy of SCE. As such, sucrose loading provides a better baseline measure of α -glucosidase activity.



Sucrose loading increased blood glucose concentrations at 30 minutes after administration. Subjects treated with SCE have reduced blood glucose and insulin.



Elevation of insulin levels following sucrose loading was also significantly inhibited by SCE compared with placebo; the inhibition was significant at 30 and 60 minutes after administration of 300 and 500 mg SCE.

During a sucrose load, SCE reduced insulin in a dose-dependent fashion and glucose was also reduced. These results indicate that SCE reduces carbohydrate absorption.

Insulin levels were reduced not only via a decreased glycemic stimulus but also by interference with other insulin releasing mechanisms.

The results in summary: SCE does not directly decrease glucose in the blood stream but was shown to inhibit intestinal absorption.


Reduction in Body Composition, Weight, and Risk of Cardiovascular Events

In the Study to Prevent NIDDM trial, the group randomly assigned to acarbose, an alpha-glucosidase inhibitor, had a reduction in:

- Blood triacylglycerols
- BMI
- Body weight
- Systolic and diastolic blood pressure
- Two Hour postprandial glucose
- Waist and hip circumferences

During a three year following of subjects, they also experienced a significantly reduced incidence of cardiovascular events and hypertension.

Limit cholesterol production: Healthy cholesterol management



Reduction in Myocardial Infarction

Seven long-term studies showed that α -glucosidase inhibitors significantly reduce the risk of myocardial infarction or any cardiovascular event

In a randomized double-blind, placebo controlled, crossover study, thirty healthy human participants were given a placebo or 1000 mg of an SCE. The extract decreased postprandial blood glucose levels after a carbohydrate-rich meal by about 13 percent at 90 min, while the plasma glucose area under the curve was decreased by about 34 percent.

SCE markedly decreased digestion and absorption of sucrose by its inhibitory action on sucrose. It reduced increases in blood glucose and insulin. Long-term studies showed significant reduction in risk for cardiovascular events including myocardial infarction.

The number of calories you burn in a day can impact weight gain. If you burn fewer calories than a slimmer person, you'll store more of what you eat as fat. Increasing the number of calories you burn can be achieved through exercise, but also through **thermogenesis**.

Capsaicin, which is responsible for the burn you feel from chili peppers, stimulates **thermogenesis** by increasing **expended energy** which burns more calories.



CAPSIMAX®

The compounds that give capsicum in red hot peppers its intense pungent heat are collectively called capsaicinoids which include the most common: capsaicin, dihydrocapsaicin and nordihydrocapsaicin.

Capsaicin alters the metabolism via activation of transient receptor potential vanilloid 1 (TRPV1.)

Capsaicinoids act as agonists of TRPV1 and imitate the effects of acute cold exposure in the body which activates brown fat and decreases body fat as a result ²⁷.

TRPV1 activation induces calcium inflow and in certain tissues increases expression of key proteins—and in this case, an uncoupling protein called thermogenin.

The calcium inflow produced by TRPV1 activation mimics stress which triggers the expression of endothelial nitric oxide synthase (eNOS) and other antioxidant enzymes. It also reduces pro-inflammatory proteins, exports cholesterol and increases vasodilation.

Capsaicin also stimulates TRPV1-expressing neurons in the GI tract activating sympathetically facilitated stimulation of brown fat which increases the metabolic rate.

Kinase-mediated phosphorylation of TRPV1 precedes increased sensitivity to both chemical and thermal stimuli. When consumed, capsaicinoids trigger the release of epinephrine and norepinephrine from the adrenal glands. This activates brown adipose tissue (brown fat) which results in thermogenesis.

Brown fat can be activated by acute cold exposure and promotes cold-induced increase in whole-body energy expenditure (shivering) which increases energy expenditure resulting in decreased body fat.

Over [90 studies](#) support that capsaicin is extremely effective in weight management. Clinical studies show capsaicin:


- Burns up to 135 calories more per day.
- Reduces caloric intake of up to 74 calories per meal.
- Reduces liver fat.
- Improves glucose tolerance.
- Decreases inflammation.
- Increases insulin sensitivity.
- Reduces visceral fat.
- Thermogenesis burns more calories daily.
- Breaks down fat.
- Increases metabolism.
- Decreases appetite.
- Increases satiety.

Capsaicinoids and Hormone Response

Approximately three milligrams of capsaicinoids are contained in one gram of dried red pepper.

When consumed, capsaicinoids initiate the sympathetic nervous system, triggering the release of epinephrine and norepinephrine from the adrenal glands.

This effect elicits responses from pathways that result in appetite control, lipolysis and thermogenesis.




Capsaicinoids and Appetite

Appetite control is achieved by effecting the complex system comprised of hormones, the nervous system, fat tissue and digestive tract.

Capsaicinoids activate TRPV1 which increases satiety and suppresses hunger.

In one study when capsaicinoids were consumed prior to or with a meal, caloric intake was reduced by around 74 calories⁵⁹.



Capsaicin and Fat Breakdown


Lipolysis is a highly controlled biochemical pathway that powers the breakdown of stored lipids. Epinephrine and norepinephrine act on lipase, perilipin and adipose triglyceride lipase all which all play a role in activating fat and breaking down triglycerides into free fatty acids and glycerol.

Fat oxidation increases due to the epinephrine and norepinephrine response that supports fat oxidation and increases in energy expenditure. Both of which have been observed between capsaicinoid treatment, illustrating a shift towards fat utilization at rest.

Studies also showed significant increase in plasma free fatty acids and glycerol compared to placebo following a low dose administration of Capsimax® in conjunction with exercise.¹¹

Many studies have confirmed an increase in lipolysis following capsaicinoid intake, including a superior decrease in abdominal adiposity with capsaicinoid intake (6mg per day) compared to placebo when subjects were randomly assigned to either for a period of 12 weeks.

The quantification of lipolysis in human subjects includes a measure of the respiratory exchange ratio (VCO_2/VO_2) and/or measurement of blood free fatty acids and glycerol concentrations. Taking in the latter may provide additional confirmation and substantiation for fat mobilization post-capsaicinoid consumption.




Capsimax® promotes lipolysis and sustains the mobilization of fats for energy production².

MAXQ
NUTRITION


Capsaicinoids and Thermogenesis

Capsaicinoids also increase thermogenesis. Thermogenesis is the production of heat energy that occurs in all tissues. Thermogenesis is a process by which utilizable cellular energy generally used to convert adenosine triphosphate (ADP) to adenosine triphosphate (ATP) is dispersed as heat, and as such, considered 'wasted'.



It is activated by amplified cellular levels of free fatty acids, which occurs during capsaicinoid consumption, shivering and exercise.¹⁴

This progression utilizes brown fat and is known as uncoupling. It is regulated by uncoupling protein-1 (UCP1), which is sometimes called thermogenin. It is an uncoupling protein found in the mitochondria of brown fat. It is used to generate heat by non-shivering thermogenesis.




UCP1 is activated in the brown fat cell by fatty acids. Fatty acids are released by thermogenesis. Fatty acids then cause the following signaling cascade: Sympathetic nervous system terminals release norepinephrine onto a Beta-3 adrenergic receptor on the plasma membrane.

This stimulates adenylyl cyclase, which triggers the conversion of ATP to cyclic AMP (cAMP).

cAMP initiates protein kinase A, causing its active C sub-units to be unbound from its regulatory R subunits³³.

Active protein kinase A, activates triacylglycerol lipase by phosphorylating it.

The lipase converts triacylglycerols into free fatty acids, which activate UCP1, overriding the inhibition caused by purine nucleotides (GDP and ADP).



At the conclusion of thermogenesis, the mitochondria oxidize the residual fatty acids until absent, UCP1 inactivates and the cell resumes its normal energy-conserving mode.

Capsaicinoids, in particular, stimulate thermogenesis by activating the sarcoplasmic reticulum Ca⁺⁺-ATP-ase (SERCA).

Hydrolysis of ATP occurs via SERCA, and in the presence of capsaicinoids, SERCA becomes uncoupled leading to greater energy production, thus activating the thermogenesis process as described above.

Capsaicinoid treatment may also stimulate vasodilation which may add to thermogenesis, as loss of heat imposes a requirement for increased metabolism.

In studies, capsaicin-rich diets have shown advantageous effects on atherosclerosis, cardiac hypertension, hypertrophy, diabetes, metabolic syndrome, non-alcoholic fatty liver, obesity and stroke risk.

STUDIES

Thermogenesis has been shown to raise resting energy expenditure by approximately 50-135 kcal/day and augment metabolic rate in conjunction with exercise and calorie-restricted dieting and exercise.^{15,16,17,28}

In one study when capsaicinoids were consumed prior to or with a meal, caloric intake was reduced by around 74 calories⁵⁹.

Studies have shown capsaicinoids increase fat oxidation which reduces visceral adipose tissue, increases free fatty acids and glycerol to power beta-oxidation and gluconeogenesis.^{8,12}

Numerous studies have confirmed an increase in lipolysis following capsaicinoid intake, including a superior decrease in abdominal adiposity with capsaicinoid intake (6mg per day) compared to placebo when subjects were randomly assigned to either for a period of 12 weeks.

For both resting energy expenditure and fat oxidation, some studies show an increase following ingestion of capsaicinoids.^{16,19}

Reductions in body fat have been observed with dosages of capsaicinoids between 2-10 mg/day.^{7,18}


Another study (Bloomer et al.) confirmed amplified circulating free fatty acids and glycerol in healthy men and women with normal weight during a four hour period after ingesting Capsimax® alone compared to a placebo. Doses were 100mg, of which 2mg were pure capsaicinoids.

Studies noted increased energy expenditure and thus increased caloric burn when 30mg daily capsaicinoids was provided along with a standardized high fat and high carbohydrate meals. Greater benefits were shown with high-fat meals^{19 Yoshioka}.

Capsimax® Has a Patented Omnibead Proven to Relieve Gastric Distress

Gastric distress when consuming capsaicinoids is well documented in studies. Because of the burn, many people may not be able to tolerate capsaicin at the doses required to achieve weight and health benefits. Capsimax® provides a patented solution with studies to support its efficacy.

Capsimax is coated with an OmniBead™ Beadlet Technology. It encapsulates the beneficial heat of concentrated highly-active, natural capsaicin in a controlled release coating, delivering effective levels of capsaicinoids without the oral and gastric burning sensation of unprotected red hot peppers.



For representative purposes only

In all studies, Capsimax® was well tolerated with no issues of oral or gastric upset.¹¹

LEANBBB™

Gamma-Butyrobetaine (GBB) is the precursor to L-carnitine production in the body. As such, it increases body's production of L-Carnitine when ingested.

The major sites of L -Carnitine biosynthesis are the liver and kidneys. Biosynthesis necessitates two essential amino acids, protein bound lysine and methionine, plus vitamin C, Vitamin B6, iron and niacin along with a sequence of catalyzed reactions ¹⁴.


In part, γ -Butyrobetaine hydroxylase (BBOX) acts as the catalyst to convert GBB into l-carnitine, which is implicated in the creation of metabolic energy from long-chain fatty acids.


L-Carnitine is shown to:

- Increase lipolysis.
- Reduce cholesterol.
- Increase energy.


[Carnitine](#) is mainly responsible for converting fatty acids into energy.

When the body needs energy, fatty acids are released from very low density lipoprotein (VLDL) and chylomicrons which are transported to cells through the assistance of L-Carnitine. Once they reach the cells, fatty acids require a vehicle to enter mitochondria where β -oxidation takes place. L-Carnitine acts as that vehicle to carry fatty acids across the mitochondrial membranes where they are oxidized for energy ¹⁴.






1) Converting a fatty acid to fatty acyl carnitine allows transport through the mitochondrial membranes.





Fatty acyl carnitine enters mitochondrial matrix



2) Fatty acyl carnitine is converted back to fatty acyl CoA within a mitochondrion.



3) Fatty acyl CoA is converted to β -ketoacyl CoA, which is split into an Acyl CoA and Acetyl CoA



End:
Acetyl CoA enters
Krebs cycle






Through this reaction carnitine propels and necessitates mitochondrial fatty acid oxidation¹³.

The inner mitochondrial membrane is impermeable to long-chain fatty acyl-CoAs and as such, fatty acids can't gain access to the intramitochondrial site of β -oxidation¹³.

As a result of carnitine's reaction, long-chain acylcarnitines produced from the acyl-CoAs are able to cross the mitochondrial membrane, recreating the acyl-CoAs in the mitochondrial matrix, and then are available as substrates for oxidation¹³.



Carnitine is concentrated in skeletal and cardiac muscle tissues that utilize fatty acids as fuel.

Carnitine transports long-chain fatty acids into the mitochondria so they can be oxidized. The result is energy. It also transports the toxic compounds generated from the cycle out of the cell to prevent accretion⁴.


Studies

A meta-analysis review by Pub-Med qualified nine studies to determine the efficacy of carnitine. Trials with mean difference (MD) of 95% confidence interval (CI) were assembled using random effect model. Results uncovered that subjects who supplemented with carnitine lost significantly more weight (MD: -1.33 kg; 95% CI: -2.09 to -0.57) and showed a decrease in body mass index (MD: -0.47 kg m(-2) ; 95% CI: -0.88 to -0.05) compared with the control group. Pub-Med established carnitine resulted in weight loss.¹

In another study, significant reductions in weight and body fat percentages were lost over 30 days when compared to a placebo group ¹⁴.

COMPARISON OF WEIGHT AND BFP WITH RESPECT TO PLACEBO AND EXPERIMENTAL GROUP:

FIGURE 1: DISTRIBUTION OF WEIGHT AND BFP BEFORE AND AFTER L-CARNITINE SUPPLEMENTATION



Dosage

Taking 100 mg of LeanGBB™ is equal to consuming 3,000 mg of carnitine. Studies show it increases carnitine concentrations in the body by up to 300 percent. ⁶



WHITE KIDNEY BEAN EXTRACT

White kidney bean extract acts as an alpha-amylase inhibitor which inhibits digestion of starches. In doing so, calories from starches are not absorbed. This effectively reduces body weight and fat levels as if on a restricted diet.

- Inhibits digestion of starches.
- Reduces fat levels.

- Reduces weight.
- Promotes healthy cholesterol and blood glucose levels.
- Reduces BMI
- Reduces adipose tissue thickness.
- Reduces waist, hip and thigh circumference.
- Maintains lean body mass.

White kidney beans are also shown to prevent or stave off weight gain during binge eating to effectively reduce or prevent weight gain, increased bad cholesterol and blood glucose.

The white kidney bean, *phaseolus vulgaris*, produces an alpha-amylase inhibitor. Studies show weight loss occurs with doses between 500 mg and 3000 mg per day¹.

Carbohydrates must be broken down into monosaccharides before being absorbed by the body. [Amylase](#) and glucosidase are two major enzymes responsible for breaking down carbs¹.

When carbs are consumed, amylase is secreted by salivary glands in the mouth and then by the pancreas in the small intestine. Amylase breaks down the carbs into oligosaccharides. Then glucosidase finalizes the breakdown into monosaccharides. Once carbs are broken down into monosaccharides, the body absorbs them.

Glucose and monosaccharides are transported to the liver, and what is not used for energy is stored as glycogen in the liver for energy or as fat.

White kidney beans prevent starch digestion by fully blocking access to the active site of the alpha-amylase enzyme.

White kidney bean extract works synergistically with **Omnilean™** because as the white kidney bean extract blocks amylase enzyme, **Omnilean™** blocks glucosidase ensuring carbs are wholly blocked from absorption.

Studies

A study on 60 slightly overweight subjects over 30 days dosed with 445 mg of white kidney bean extract taken once per day. Subjects were carbohydrate rich diets of 2,000-2,200 calories per day.

After 30 days, subjects had significantly greater reduction of adipose tissue thickness, body weight, BMI, fat mass, and waist/hip/ thigh circumferences. They also maintained lean body mass compared to placebo.

Table 4

Effect of Phaseolus vulgaris-containing extract vs. control dietary supplement on the body composition of overweight subjects

Measured Parameter	Test (n=30)	Control (n=29)	p-value
Body weight (kg)	-2.93 ± 1.16	-0.35 ± 0.38	<0.001
Fat mass (kg)	-2.4 ± 0.67	-0.16 ± 0.33	<0.001
Lean body mass (kg)	-0.53 ± 0.45	-0.19 ± 0.17	<0.05
Waist circumference (cm)	-2.93 ± 2.13	-0.47 ± 0.39	<0.001
Hip circumference (cm)	-1.48 ± 0.66	-0.10 ± 0.47	<0.001
Thigh (right) circumference (cm)	-0.95 ± 0.80	-0.26 ± 0.46	<0.001
Adipose tissue thickness (via skin echogram) (mm)	-4.2 ± 6.51	-0.66 ± 2.81	<0.001

([Source](#))

The group lost on average, 6.6 pounds in body weight, 6 pounds of fat mass, 1.25 inches from the waist, and 1 inch from the hips.

In another study, white kidney bean extract was shown to decrease digestion of dietary starch.

In another study, it completely inhibited amylase activity [2].

An additional study showed subjects ingested 50 g rice starch and on the next day they ingested starch with 5 g or 10 g white bean extract. The white bean extract significantly reduced amylase activity by more than 95 percent. Acting within fifteen minutes and lasting up to two hours it also:

- Increased delivery of carbs to small bowel by 22-24 percent.
- Increased hydrogen concentration in breath from 30-90 minutes post-meal (indicator of carb malabsorption).
- Reduced post-meal blood sugar by 85 percent.
- Decreased post-meal blood insulin levels. [2].

In a longer-term study over three weeks, subjects were given white kidney bean extract reducing blood sugar levels more than thirty percent with a dose of four to six grams per meal. [2]

In some studies, diarrhea and gastrointestinal symptoms occurred the first day of administration but resolved after taking over the course of a few days.


HMB

β-Hydroxy β-Methylbutyrate (HMB) is a metabolite of the amino acid leucine and preserves muscle mass.

During weight loss, muscle mass is also lost. HMB lowers muscle proteolysis following resistance training, and increases gains in lean body mass and strength.¹

- Approximately five percent of leucine is metabolized into HMB ⁹. As such, to reap the benefits of HMB, 60 grams of leucine would be needed to harvest the studied and recommended dosage of 3 grams of HMB from the metabolic process.

- Increases aerobic capacity of muscles.
- Enhances immune response.¹⁸⁻²⁴



Studies

In a study on muscle metabolism and performance, subjects took 0, 1.5 grams or 3 grams of HMB daily. Subjects strength trained 3 times per week. Results showed reduced muscle damage, protein degradation and increases in lean body mass with most marked results at 3 gram doses.³⁷

In another study over 7 weeks, lean body mass was significantly increased and strength markedly increased with a tolerated 15 pound increase in weights on bench press.³⁷

HMB decreases body fat by more than twice the rate of non supplemented subjects (-1.1% vs. -.5%) and increased lean body mass (1.4 vs. .9 kg) in studies with a 55 percent increase in bench press performance.³⁹

Strength was increased more than triple-fold in one study showing leg extension power increased from 4.8 percent to 14.7 percent after 9 weeks of strength training.⁴⁰

In a meta-analysis study for supplements claiming to increase lean body mass and strength, studies between 1967 and 2001 were reviewed. 250 supplements were reviewed, only 6 met the qualifying criteria and only creatine and HMB had adequate evidence to support increases in lean body mass and strength.⁴²

Dosage


Most studies advise taking 3 grams of HMB daily. [32,37,42,44](#)

DIGESEB™

DigeSEB™ is an advanced blend of food grade digestive enzymes from non-animal sources. As a digestive enzyme, it is formulated to aid in the digestion of fats, carbohydrates and proteins. The comprehensive combination of **Amylase** (carb break down), **Cellulase** (fiber break down), **Lactase** (dairy breakdown), **Lipase** (fat breakdown), **Protease** (protein breakdown) helps the body break down foods in the gastrointestinal tract to combat indigestion, bloating, abdominal discomfort and gas.

Amylase, Cellulase and Lactase digest complex sugars, starches and non-starch polysaccharides ¹.

DigeSEB formula contains an acid stable Lipase derived from plant sources that is significantly more effective than pancreatin in digestion of lipids¹. Its protease hydrolyzes proteins into smaller peptides and free amino acids.




DigeSEB :

- Aids in digestion of carbs, fiber, dairy, fat and protein.
- Relieves digestive discomfort through aiding in digestion.
- Has broad specificity for legumes, milk, soy, cereal grains, meat and other foods.
- Is effective in a pH range of 3 to 9, which allows it to work throughout the wide variations in pH in the digestive tract.

Lipase Breaks down Fat


Lipase carries out an essential role in the digestion, transport and processing of fats..

Lipase catalyzes the hydrolysis of fats by converting triglyceride substrates in oils into monoglycerides and fatty acids.



Protease Breaks Down Protein

Protease carries out proteolysis which is the breaking down of protein through by hydrolysis of peptide bonds.



Lactase Breaks Down Dairy

Lactase is necessary to the digestion of whole milk. It breaks down lactose, the sugar responsible for giving milk its sweet taste.


Lactase hydrolyzes disaccharide lactose into galactose and glucose molecules.

Cellulase Breaks Down Fiber

Cellulase breaks down the fiber into monosaccharides. Fiber is often difficult to digest and its consumption results in digestive issues like bloating and gas.

Amylase Breaks Down Carbohydrates

Amylase is produced in the pancreas and salivary glands to break down starch into disaccharides and trisaccharides.



DigesSEB is a Synergistic Ingredient of Capsilean

DigeSEB is a synergistic ingredient in Capsilean's formula. With Omnilean and white kidney bean extract having some digestive side effects like bloating and gas, due to undigested carbohydrates, DigeSEB reduces the effects with enzymatic resolve.

Studies

In a double-blind trial a timed-release form of enzymes were given to subjects to consume before and after a meal. Three capsules were taken by each subject totaling 30,000 USP units of [lipase](#),

112,500 USP units of protease, and 99,600 USP units of amylase. The results showed significantly reduced bloating, gas and fullness after consuming a high-fat meal.

Studies also show that in people who are healthy or afflicted by gastrointestinal disease, supplementation with digestive enzymes increases digestion and improves bioavailability of carbs and proteins.

BIOPERINE™

BioPerine® is a patented extract obtained from black pepper fruits and is used as a bioavailability enhancer to improve nutrient absorption by at least 30%⁰.

BioPerine® is a patented extract obtained from black pepper fruits (*Piper nigrum*) standardized minimum to 95% Piperine.

Increasing absorption of a drug or nutrient can increase its therapeutic benefits and reduce the overall dose necessary to deliver those benefits.

Poorly bioavailable drugs aren't effective because a large portion of a dose will not reach the blood to release benefits without very large doses. These larger doses pose side effects that can be serious. The discovery of piperine in 1979 as a bioavailability enhancer changed the perception of absorption and efficacy.

Piperine interacts with enzymes that partake in metabolism of supplements and drugs. Because each drug varies in the way the body metabolizes it, piperine works differently for each drug. In part, it interacts with oxidative phosphorylation processes and metabolic pathways to slow down the metabolism and biodegradation of drugs. It stimulates absorption by exciting gut amino acid transporters, hinders the cell pump in control of drug elimination from cells and impedes intestinal production of glucuronic acid. As a result, higher levels of the drug make it to the blood and more bioavailable ⁶⁶.

Studies

Piperine was found to increase bioavailability of various drugs ranging from 30 percent to 200 percent⁶⁶.

Research has shown that piperine increases curcumin bioavailability by nearly ten-fold ⁶⁶.

A study evaluated the effect of 20 mg piperine on carbamazepine in doses of 300 mg and 500 mg. Results showed that piperine significantly increased the mean plasma concentrations of carbamazepine in both groups of doses ³⁸.

Results of one study in rats showed piperine increases the oral exposure of fexofenadine by 180 percent to 190 percent and bioavailability by ~200 percent.

In another study on piperine and curcumin bioavailability, subjects were given a dose 20 mg/kg and 20 mg showing an increase in bioavailability of 2000 percent⁴¹.

In a crossover, placebo-controlled study subjects were given piperine 20mg or placebo each morning for 6 days, and on day 7, nevirapine 200mg plus piperine 20mg or nevirapine plus placebo. Results showed values of nevirapine were increased by 120 percent to 170 percent ⁴².

In a study on metronidazole and piperine, increases of 57 percent and 88.53 percent in peak plasma levels and AUC respectively of metronidazole were shown.

Another study reviewed piperine's impact on resveratrol of 100 mg/kg in mice. Results showed resveratrol was enhanced to 229 percent and the maximum serum concentration increased to 1544 percent⁵¹.

Dose

Studies show bioenhancement activity at 15 -20 mg total piperine per day⁶¹.

References:

Capsimax

1. **Omniaactives.com**
2. A Mori, S. Lehmann et al., Cancer Res, 66. 6, 3222-3229 (2006).
3. A Szallasi, P.M. Blumberg, Pharmacol Rev, 51. 2, 159-212 (1999).
4. Ahuja KD, Robertson IK, Geraghty DP, Ball MJ. Effects of chili consumption on postprandial glucose, insulin, and energy metabolism. Am J Clin Nutr. 2006 Jul; 84(1):63-9.
5. B.V. Thomas, A.A. Schreiber et al., J Agric Food Chem, 46. 2655--2663 (1998).
6. Belza A, Frandsen E, Kondrup J. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Int J Obes (Lond). 2007 Jan; 31(1):121-30. 2. NG et al., 2013
7. Bloomer RJ, Canale RE, Shastri S, Suvarnapathki S. Effect of oral intake of capsaicinoid beadlets on catecholamine secretion and blood markers of lipolysis in healthy adults: a randomized placebo controlled, double-blind, crossover study. Lipid in health and Dis. 2010;9(72): 1-7.
8. De Lourdes Reyes-Escogido, M, Gonzalez-Mondragon, ED and Vazquez-Tzompantzi, E . Chemical and pharmacological aspects of capsaicin. Molecules. 2011;16: 1253-1270.
9. E. Idelevich, W. Kirch et al., Ther Adv Cardiovasc Dis, 3. 1, 75-90 (2009).
10. F.W. Leung, Life Sci, 83. 1-2, 1-5 (2008).
11. G. Fragasso, A. Palloschi et al., J Cardiovasc Pharmacol, 44. 3, 340-347 (2004).
12. Galgani JE, Ravussin E. Effect of dihydrocapsiate on resting metabolic rate in humans. Am J Clin Nutr. 2010; 92:1089–1093.
13. H. Sasai, Y. Katayama et al., Diabetes Res Clin Pract, 84. 3, 230-238 (2009).
14. H.C. Reinbach, A. Smeets et al., Clin Nutr, 28. 3, 260-265 (2009).

15. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. *Nature Medicine*. 2013; 19:1252–1263.
16. <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-foods-gen/documents/document/ucm269479.pdf>
17. Huang W, Cheang WS, Wang X, Lei L, Liu Y, Ma KY, Zheng F, Huang Y, Chen ZY. Capsaicinoids but not their analogue capsinoids lower plasma cholesterol and possess beneficial vascular activity. *J Agric Food Chem*. 2014; 62(33):8415-20.
18. Inoue N, Matsunaga Y, Satoh H, Takahashi M. Enhanced energy expenditure and fat oxidation in humans with high BMI scores by the ingestion of novel and non-pungent capsaicin analogues (capsinoids) *Biosci Biotechnol Biochem*. 2007; 71:380–389.
19. J.E. Blundell, N.A. King, *Med Sci Sports Exerc*, 31. 11 Suppl, S573-83 (1999).
20. J.W. Jocken, E.E. Blaak, *Physiol Behav*, 94. 2, 219-230 (2008).
21. Johnson W Jr. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. *Int J Toxicol*. 2007; 26 Suppl 1:3-106.
22. Josse AR, Sherriffs SS, Holwerda AM, Andrews R, Staples AW, Phillips SM. Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise. *Nutr Metab*. 2010; 7:65.
23. K. Kobata, T. Todo et al., *J Agric Food Chem*, 46. 1695-1697 (1998).
24. K. Sato, S.S. Sasaki et al., *J Agric Food Chem*, 47. 11, 4665-4668 (1999).
25. Lejeune MP, Kovacs EM, Westerterp-Plantenga MS. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *Br J Nutr*. 2003 Sep; 90(3):651-59.
26. Lopez H, Ziegenfuss TN, Hofheins JE, Habowski S, Arent SM, Weir JP, Ferrando AA. Eight weeks of supplementation with a multi-ingredient weight loss product enhances body composition, reduces hip and waist girth, and increases energy levels in overweight men and women. *J Int Soc Sports Nut*. 2013; 10: 1-14.
27. Ludy MJ, Moore GE, Mattes RD. The effects of capsaicin and capsiate on energy balance: critical review and meta-analyses of studies in humans. *Chem Senses*. 2011; 37(2): 103-21.
28. Saito M. *Adv Food Nutr Res*. 2015;76:1-28. doi: 10.1016/bs.afnr.2015.07.002. Epub 2015 Sep 26. Review
29. M. Adams, (2008) Retrieved March/30, 2005, <http://www.naturalnews.com/006133.html>
30. M. Russek, C. Vega et al., *Appetite*, 9. 2, 119-126 (1987).
31. M. Yoshioka, E. Doucet et al., *Br J Nutr*, 85. 2, 203-211 (2001).
32. M. Yoshioka, K. Lim et al., *J Nutr Sci Vitaminol (Tokyo)*, 41. 6, 647-656 (1995).
33. M. Yoshioka, S. St-Pierre et al., *Br J Nutr*, 80. 6, 503-510 (1998).
34. M. Yoshioka, S. St-Pierre et al., *Br J Nutr*, 82. 2, 115-123 (1999).
35. M.L. Dansinger, J.A. Gleason et al., *JAMA*, 293. 1, 43-53 (2005).
36. M.L. Wahlqvist, N. Wattanapenpaiboon, *Lancet*, 358. 9279, 348-349 (2001).
37. M.P. Lejeune, E.M. Kovacs et al., *Br J Nutr*, 90. 3, 651-659 (2003).
38. M.S. Westerterp-Plantenga, A. Smeets et al., *Int J Obes (Lond)*, 29. 6, 682-688 (2005).
39. M.W. Turk, K. Yang et al., *J Cardiovasc Nurs*, 24. 1, 58-80 (2009).
40. Mahmmoud YA. Capsaicin stimulates uncoupled ATP hydrolysis by the sarcoplasmic reticulum calcium pump. *J Biol Chem*. 2008 Aug 1;283(31):21418-26.
41. N. Inoue, Y. Matsunaga et al., *Biosci Biotechnol Biochem*, 71. 2, 380-389 (2007).

42. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. *JAMA*. 2014; 311(8):806-814.
43. Othman ZA, Hadj Ahmed YB, Habila MA, Ghafar AA. Determination of capsaicin and dihydrocapsaicin in capsicum fruit samples using high performance liquid chromatography. *Molecules*. 2011;16:8919-8929.
44. P. Dandona, P. Mohanty et al., *J Clin Endocrinol Metab*, 86. 1, 355-362 (2001).
45. P. Poirier, J.P. Despres, *Cardiol Clin*, 19. 3, 459-470 (2001).
46. S. Hachiya, F. Kawabata et al., *Biosci Biotechnol Biochem*, 71. 3, 671-676 (2007).
47. S. Low, M.C. Chin et al., *Annals of the Academy of Medicine, Singapore*, 38. 1, 57-59 (2009).
48. S. Snitker, Y. Fujishima et al., *Am J Clin Nutr*, 89. 1, 45-50 (2009).
49. S. Yazawa, N. Suetome et al., *Japanese Society for Horticultural Science*, 58. 601-607 (1989).
50. Sahoo SK, Shaikh SA, Sopariwala DH, Bal NC, Periasamy M. Sarcolipin protein interaction with sarco(endo)plasmic reticulum Ca²⁺ ATPase (SERCA) is distinct from phospholamban protein, and only sarcolipin can promote uncoupling of the SERCA pump. *J Biol Chem*. 2013 Mar 8; 288(10):6881-6889.
51. Shin KO, Moritani T. Alterations of autonomic nervous activity and energy metabolism by capsaicin ingestion during aerobic exercise in healthy men. *J Nutr Sci Vitaminol*. 2007 Apr; 53(2):124-32.
52. Smeets AJ, Westerterp-Plantenga MS. The acute effects of a lunch containing capsaicin on energy and substrate utilisation, hormones, and satiety. *Eur J Nutr*. 2009 Jun;48(4):229-34.
53. Snitker S, Fujishima Y, Shen H, Ott S, Pi-Sunyer X, Furuhashi Y, Sato H, Takahashi M. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. *Am J Clin Nutr*. 2009; 89:45-50.
54. T. Kawada, T. Suzuki et al., *Toxicol Appl Pharmacol*, 72. 3, 449-456 (1984).
55. T. Matsumoto, C. Miyawaki et al., *J Nutr Sci Vitaminol (Tokyo)*, 46. 6, 309-315 (2000).
56. T. Osaka, T.H. Lee et al., *Neuroreport*, 11. 11, 2425-2428 (2000).
57. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. *Nat Rev Drug Discov*. 2008; 7(8):678-93.
58. V.S. Govindarajan, M.N. Sathyanarayana, *Critical Reviews in Food Science and Nutrition*, 29. 6, 435-474 (1991).
59. Veronesi B and Oortgiesen. The TRPV1 Receptor: Target of Toxicants and Therapeutics. *Toxicol Sci*. 2006; 89(1): 1-3.
60. W. Robbins, *Clin J Pain*, 16. 2 Suppl, S86-9 (2000).
61. Whiting S, Derbyshire E, Tiwari BK. Capsaicinoids and capsinoids. A potential role for weight management? A systematic review of the evidence. *Appetite*. 2012 Oct; 59(2):341-348.
62. Winther, Anne-Marie L; Bubltz, Maike; Karlsen, Jesper L; Møller, Jesper V; Hansen, John B; Nissen, Poul; Buch-Pedersen, Morten J The sarcolipin-bound calcium pump stabilizes calcium sites exposed to the cytoplasm. *Nature*. 2013 Mar 14; 495(7440):265-269.
63. Y.A. Mahmmoud, *J Biol Chem*, 283. 31, 21418-21426 (2008).
64. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, Tepel M. Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. *Circ Res*. 2007 Apr 13;100(7):1063-70.

LeanGBB

1. Pooyandjoo M, Nouhi M, Shab-Bidar S, Djafarian K, Olyaeemanesh A. *Obes Rev*. 2016 Oct;17(10):970-6. doi: 10.1111/obr.12436. Epub 2016 Jun 22. Review. [The effect of \(L-\)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials.](#)

2. Allan M. Evans, Gianfranco Fornasini. Pharmacokinetics of L-Carnitine. Clin Pharmacokinet 2003; 42 (11): 941-967
3. Olson AL, Rebouche CJ. gamma-Butyrobetaine hydroxylase activity is not rate limiting for carnitine biosynthesis in the human infant. J Nutr. 1987 Jun;117(6):1024-31.
4. Rebouche CJ, Bosch EP, Chenard CA, Schabold KJ, Nelson SE. Utilization of dietary precursors for carnitine synthesis in human adults. J Nutr. 1989 Dec;119(12):1907-13.
5. Roghaieh K, Minoo A. Validation of a Stability-Indicating RP-HPLC Method for Determination of L-Carnitine in Tablets. International Scholarly Research Notices. 2014 October; Volume 2014, Article ID 481059, 7 pages
6. Sandor A. Butyrobetaine is equal to L-carnitine in elevating L-carnitine levels in rats. Biochim Biophys Acta. 1991 May 8;1083(2):135-8.
7. Hiatt WR. Carnitine and peripheral arterial disease. Ann NY Acad Sci 2004;1033:92-8.
8. Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology 2006;106:215-23.
9. DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc 2013. Apr 15. [Epub ahead of print]
10. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol 1999;34:1618-24.
11. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, Cooke JP, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 2001;110:616-22.
12. Brass EP, Koster D, Hiatt WR, Amato A. A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vasc Med 2013;18:3-12.
13. Brass, E. P., Hoppel, C. L., & Hiatt, W. R. (1994). Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. *Clinical Pharmacology & Therapeutics*, 55(6), 681-692.
14. Kalpana and Aruna Effects of L Carnitine (Neutraceutical) In Weight Management among Overweight and Obese Adults of Age between 20 –45yrs –A Comparative Study in Chennai and Tirupathi. International Journal of Scientific and Research Publications, Volume 2, Issue 9, September 2012.

White Kidney Bean Extract

1. Celleno, L., Tolaini, M. V., D'Amore, A., Perricone, N. V., & Preuss, H. G. (2007). A Dietary Supplement Containing Standardized *Phaseolus vulgaris* Extract Influences Body Composition of Overweight Men and Women. *International Journal of Medical Sciences*, 4(1), 45–52.
2. M. L. Barrett and J. K. Udani, "A proprietary α -amylase inhibitor from white bean (*Phaseolus vulgaris*): a review of clinical studies on weight loss and glycemic control," Nutrition Journal, vol. 10, article 24, 2011.
3. [Purification and Properties of Phaseolamin, an inhibitor of alpha-amylase, from the Kidney Bean *Phaseolus vulgaris*](#)
4. Ishimoto M, Yamada T, Kaga A [Insecticidal activity of an alpha-amylase inhibitor-like protein resembling a putative precursor of alpha-amylase inhibitor in the common bean, *Phaseolus vulgaris* L.](#) *Biochim Biophys Acta*. (1999)

5. [Characterization of a purified \$\alpha\$ -amylase inhibitor from white kidney beans \(*Phaseolus vulgaris*\)](#)
6. Liener IE, Donatucci DA, Tarcza JC [Starch blockers: a potential source of trypsin inhibitors and lectins](#) . *Am J Clin Nutr.* (1984)
7. Layer P, Carlson GL, DiMagno EP [Partially purified white bean amylase inhibitor reduces starch digestion in vitro and inactivates intraduodenal amylase in humans](#) . *Gastroenterology.* (1985)
8. Layer P, Zinsmeister AR, DiMagno EP [Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans](#) . *Gastroenterology.* (1986)
9. [Subchronic oral toxicity of a standardized white kidney bean \(*Phaseolus vulgaris*\) extract in rats](#)
10. Hangen L, Bennink MR [Consumption of black beans and navy beans \(*Phaseolus vulgaris*\) reduced azoxymethane-induced colon cancer in rats](#) . *Nutr Cancer.* (2002)
11. Pusztai A, *et al* [Lipid accumulation in obese Zucker rats is reduced by inclusion of raw kidney bean \(*Phaseolus vulgaris*\) in the diet](#) . *Br J Nutr.* (1998)
12. Layer P, *et al* [Effect of a purified amylase inhibitor on carbohydrate tolerance in normal subjects and patients with diabetes mellitus](#) . *Mayo Clin Proc.* (1986)
13. Boivin M, *et al* [Gastrointestinal and metabolic effects of amylase inhibition in diabetics](#) . *Gastroenterology.* (1988)
14. Udani J, Hardy M, Madsen DC [Blocking carbohydrate absorption and weight loss: a clinical trial using Phase 2 brand proprietary fractionated white bean extract](#) . *Altern Med Rev.* (2004)
15. [A Dietary Supplement Containing Standardized *Phaseolus vulgaris* Extract Influences Body Composition of Overweight Men and Women](#)

HMB

1. Gabriel Wilson, Jacob Wilson, Anssi Manninen Nutrition & Metabolism, 2008, Volume 5, Number 1, Page 1
2. Abumrad NN, Rathmacher JA [Exercise-Induced Muscle Damage is Not Attenuated by Maximuscle \$\beta\$ -Hydroxy- \$\beta\$ -Methylbutyrate-1000™ Supplementation](#) . *J Strength Cond Res.* (2011)
3. Aversa Z, *et al* [\$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate \(HMB\) attenuates muscle and body weight loss in experimental cancer cachexia](#) . *Int J Oncol.* (2011)
4. Aversa Z, *et al* [\$\beta\$ -Hydroxy- \$\beta\$ -methylbutyrate \(HMB\) prevents dexamethasone-induced myotube atrophy](#) . *Biochem Biophys Res Commun.* (2012)
5. Baier S, *et al* [Year-long changes in protein metabolism in elderly men and women supplemented with a nutrition cocktail of beta-hydroxy-beta-methylbutyrate \(HMB\), L-arginine, and L-lysine](#) . *JPEN J Parenter Enteral Nutr.* (2009)
6. Baxter JH, *et al* [Dietary toxicity of calcium beta-hydroxy-beta-methyl butyrate \(CaHMB\)](#) . *Food Chem Toxicol.* (2005)
7. Bohé J, *et al* [Human muscle protein synthesis is modulated by extracellular, not intramuscular amino acid availability: a dose-response study](#) . *J Physiol.* (2003)
8. Buse MG, Weigand DA [Studies concerning the specificity of the effect of leucine on the turnover of proteins in muscles of control and diabetic rats](#) . *Biochim Biophys Acta.* (1977)
9. [Calcium \$\beta\$ -Hydroxy- \$\beta\$ -Methylbutyrate](#)
10. Clark RH, *et al* [Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study](#) . *JPEN J Parenter Enteral Nutr.* (2000)
11. Dardevet D, *et al* [Stimulation of in vitro rat muscle protein synthesis by leucine decreases with age](#) . *J Nutr.* (2000)

12. Deutz NE, *et al* [Effect of \$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate \(HMB\) on lean body mass during 10 days of bed rest in older adults](#) . *Clin Nutr.* (2013)
13. [EFFECT OF \$\beta\$ -HYDROXY- \$\beta\$ -METHYLBUTYRATE SUPPLEMENTATION DURING ENERGY RESTRICTION IN FEMALE JUDO ATHLETES](#)
14. Eley HL, *et al* [Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli](#) . *Am J Physiol Endocrinol Metab.* (2007)
15. Eley HL, Russell ST, Tisdale MJ [Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by beta-hydroxy-beta-methylbutyrate](#) . *Am J Physiol Endocrinol Metab.* (2008)
16. Eley HL, Russell ST, Tisdale MJ [Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor- \$\alpha\$ and angiotensin II by beta-hydroxy-beta-methylbutyrate](#) . *Am J Physiol Endocrinol Metab.* (2008)
17. Elia D, *et al* [Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: Involvement of MAPK/ERK and PI3K/Akt pathways](#) . *Biochim Biophys Acta.* (2007)
18. Filho JC, *et al* [Simultaneous measurements of free amino acid patterns of plasma, muscle and erythrocytes in healthy human subjects](#) . *Clin Nutr.* (1997)
19. Flakoll P, *et al* [Effect of beta-hydroxy-beta-methylbutyrate, arginine, and lysine supplementation on strength, functionality, body composition, and protein metabolism in elderly women](#) . *Nutrition.* (2004)
20. Fuller JC Jr, *et al* [Free acid gel form of \$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate \(HMB\) improves HMB clearance from plasma in human subjects compared with the calcium HMB salt](#) . *Br J Nutr.* (2011)
21. Fuller JC Jr, *et al* [Vitamin D status affects strength gains in older adults supplemented with a combination of \$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate, arginine, and lysine: a cohort study](#) . *JPEN J Parenter Enteral Nutr.* (2011)
22. Gallagher PM, *et al* [Beta-hydroxy-beta-methylbutyrate ingestion, Part I: effects on strength and fat free mass](#) . *Med Sci Sports Exerc.* (2000)
23. Gallagher PM, *et al* [Beta-hydroxy-beta-methylbutyrate ingestion, part II: effects on hematology, hepatic and renal function](#) . *Med Sci Sports Exerc.* (2000)
24. Green DR [Apoptotic pathways: ten minutes to dead](#) . *Cell.* (2005)
25. [Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers](#)
26. Hoffman JR, *et al* [Effects of beta-hydroxy beta-methylbutyrate on power performance and indices of muscle damage and stress during high-intensity training](#) . *J Strength Cond Res.* (2004)
27. [International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate \(HMB\)](#)
28. Jejurikar SS, *et al* [Aging increases the susceptibility of skeletal muscle derived satellite cells to apoptosis](#) . *Exp Gerontol.* (2006)
29. Jiang Y, *et al* [Opposite roles of myocardin and atrogen-1 in L6 myoblast differentiation](#) . *J Cell Physiol.* (2013)
30. Jówko E, *et al* [Creatine and beta-hydroxy-beta-methylbutyrate \(HMB\) additively increase lean body mass and muscle strength during a weight-training program](#) . *Nutrition.* (2001)
31. Kim JS, *et al* [\$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate did not enhance high intensity resistance training-induced improvements in myofiber dimensions and myogenic capacity in aged female rats](#) . *Mol Cells.* (2012)

32. Kornasio R, et al [Beta-hydroxy-beta-methylbutyrate \(HMB\) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways](#) . *Biochim Biophys Acta*. (2009)
33. Krajnak K, et al [Proapoptotic factor Bax is increased in satellite cells in the tibialis anterior muscles of old rats](#) . *Muscle Nerve*. (2006)
34. Kreider RB, et al [Effects of calcium beta-hydroxy-beta-methylbutyrate \(HMB\) supplementation during resistance-training on markers of catabolism, body composition and strength](#) . *Int J Sports Med*. (1999)
35. Lamboley CR, Royer D, Dionne IJ [Effects of beta-hydroxy-beta-methylbutyrate on aerobic-performance components and body composition in college students](#) . *Int J Sport Nutr Exerc Metab*. (2007)
36. May PE, et al [Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine](#) . *Am J Surg*. (2002)
37. Nissen S, et al [beta-hydroxy-beta-methylbutyrate \(HMB\) supplementation in humans is safe and may decrease cardiovascular risk factors](#) . *J Nutr*. (2000)
38. Nissen S, et al [Effect of leucine metabolite beta-hydroxy-beta-methylbutyrate on muscle metabolism during resistance-exercise training](#) . *J Appl Physiol*. (1996)
39. Nunan D, Howatson G, van Someren KA [Exercise-induced muscle damage is not attenuated by beta-hydroxy-beta-methylbutyrate and alpha-ketoisocaproic acid supplementation](#) . *J Strength Cond Res*. (2010)
40. O'Connor DM, Crowe MJ [Effects of beta-hydroxy-beta-methylbutyrate and creatine monohydrate supplementation on the aerobic and anaerobic capacity of highly trained athletes](#) . *J Sports Med Phys Fitness*. (2003)
41. O'Connor DM, Crowe MJ [Effects of six weeks of beta-hydroxy-beta-methylbutyrate \(HMB\) and HMB/creatine supplementation on strength, power, and anthropometry of highly trained athletes](#) . *J Strength Cond Res*. (2007)
42. Paddon-Jones D, Keech A, Jenkins D [Short-term beta-hydroxy-beta-methylbutyrate supplementation does not reduce symptoms of eccentric muscle damage](#) . *Int J Sport Nutr Exerc Metab*. (2001)
43. Panton LB, et al [Nutritional supplementation of the leucine metabolite beta-hydroxy-beta-methylbutyrate \(hmb\) during resistance training](#) . *Nutrition*. (2000)
44. Peterson AL, et al [In vitro exposure with beta-hydroxy-beta-methylbutyrate enhances chicken macrophage growth and function](#) . *Vet Immunol Immunopathol*. (1999)
45. Pimentel GD, et al [β-Hydroxy-β-methylbutyrate \(HMB\) supplementation stimulates skeletal muscle hypertrophy in rats via the mTOR pathway](#) . *Nutr Metab (Lond)*. (2011)
46. Pinheiro CH, et al [Metabolic and functional effects of beta-hydroxy-beta-methylbutyrate \(HMB\) supplementation in skeletal muscle](#) . *Eur J Appl Physiol*. (2012)
47. Portal S, et al [The effect of HMB supplementation on body composition, fitness, hormonal and inflammatory mediators in elite adolescent volleyball players: a prospective randomized, double-blind, placebo-controlled study](#) . *Eur J Appl Physiol*. (2011)
48. Pugazhenth S, et al [Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein](#) . *J Biol Chem*. (2000)
49. Ransone J, et al [The effect of beta-hydroxy beta-methylbutyrate on muscular strength and body composition in collegiate football players](#) . *J Strength Cond Res*. (2003)
50. Rathmacher JA, et al [Supplementation with a combination of beta-hydroxy-beta-methylbutyrate \(HMB\), arginine, and glutamine is safe and could improve hematological parameters](#) . *JPEN J Parenter Enteral Nutr*. (2004)

51. Russell ST, Tisdale MJ [Mechanism of attenuation by beta-hydroxy-beta-methylbutyrate of muscle protein degradation induced by lipopolysaccharide](#) . *Mol Cell Biochem.* (2009)
52. Sabourin PJ, Bieber LL [Formation of beta-hydroxyisovalerate by an alpha-ketoisocaproate oxygenase in human liver](#) . *Metabolism.* (1983)
53. Siwicki AK, *et al* [In vitro effects of beta-hydroxy-beta-methylbutyrate \(HMB\) on cell-mediated immunity in fish](#) . *Vet Immunol Immunopathol.* (2000)
54. Slater G, *et al* [Beta-hydroxy-beta-methylbutyrate \(HMB\) supplementation does not affect changes in strength or body composition during resistance training in trained men](#) . *Int J Sport Nutr Exerc Metab.* (2001)
55. Smith HJ, Mukerji P, Tisdale MJ [Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss](#) . *Cancer Res.* (2005)
56. Stein TP, *et al* [Attenuation of the protein wasting associated with bed rest by branched-chain amino acids](#) . *Nutrition.* (1999)
57. Stein TP, *et al* [Branched-chain amino acid supplementation during bed rest: effect on recovery](#) . *J Appl Physiol.* (2003)
58. Tews DS, Goebel HH [DNA-fragmentation and expression of apoptosis-related proteins in muscular dystrophies](#) . *Neuropathol Appl Neurobiol.* (1997)
59. [The Mitogenic and Myogenic Actions of Insulin-like Growth Factors Utilize Distinct Signaling Pathways](#)
60. Thomson JS, Watson PE, Rowlands DS [Effects of nine weeks of beta-hydroxy-beta-methylbutyrate supplementation on strength and body composition in resistance trained men](#) . *J Strength Cond Res.* (2009)
61. Tidball JG, *et al* [Apoptosis precedes necrosis of dystrophin-deficient muscle](#) . *J Cell Sci.* (1995)
62. Tischler ME, Desautels M, Goldberg AL [Does leucine, leucyl-tRNA, or some metabolite of leucine regulate protein synthesis and degradation in skeletal and cardiac muscle](#) . *J Biol Chem.* (1982)
63. Van Koeving M, Nissen S [Oxidation of leucine and alpha-ketoisocaproate to beta-hydroxy-beta-methylbutyrate in vivo](#) . *Am J Physiol.* (1992)
64. van Someren KA, Edwards AJ, Howatson G [Supplementation with beta-hydroxy-beta-methylbutyrate \(HMB\) and alpha-ketoisocaproic acid \(KIC\) reduces signs and symptoms of exercise-induced muscle damage in man](#) . *Int J Sport Nutr Exerc Metab.* (2005)
65. Vukovich MD, *et al* [beta-hydroxy-beta-methylbutyrate \(HMB\) kinetics and the influence of glucose ingestion in humans](#) . *J Nutr Biochem.* (2001)
66. Vukovich MD, Stubbs NB, Bohlken RM [Body composition in 70-year-old adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of young adults](#) . *J Nutr.* (2001)
67. Wilkinson DJ, *et al* [Effects of Leucine and its metabolite, \$\beta\$ -hydroxy- \$\beta\$ -methylbutyrate \(HMB\) on human skeletal muscle protein metabolism](#) . *J Physiol.* (2013)
68. Wilson JM, *et al* [Acute and timing effects of beta-hydroxy-beta-methylbutyrate \(HMB\) on indirect markers of skeletal muscle damage](#) . *Nutr Metab (Lond).* (2009)
69. Wilson JM, *et al* [Beta-hydroxy-beta-methyl-butyrate blunts negative age-related changes in body composition, functionality and myofiber dimensions in rats](#) . *J Int Soc Sports Nutr.* (2012)
70. Wilson JM, *et al* [\$\beta\$ -Hydroxy- \$\beta\$ -methylbutyrate free acid reduces markers of exercise-induced muscle damage and improves recovery in resistance-trained men](#) . *Br J Nutr.* (2013)
71. Zanchi NE, Nicastro H, Lancha AH Jr [Potential antiproteolytic effects of L-leucine: observations of in vitro and in vivo studies](#) . *Nutr Metab (Lond).* (2008)

72. Wilson, J. M., Fitschen, P. J., Campbell, B., Wilson, G. J., Zanchi, N., Taylor, L., ... Antonio, J. (2013). International Society of Sports Nutrition Position Stand: beta-hydroxy-beta-methylbutyrate (HMB). *Journal of the International Society of Sports Nutrition*, 10, 6. <http://doi.org/10.1186/1550-2783-10-6>

Bioperine

<http://www.bioperine.com/index.php/aboutbioperine>

1. Schmidt EF and Smith DA. Is pharmaceutical R&D is just a game of chance or can strategy make a difference? *Drug Discov Today* 2004;9:18–26.
 2. Hughes B. 2008 FDA drug approvals. *Nat Rev Drug Discov* 2009;8:93–96. <http://dx.doi.org/10.1038/nrd2813>
 3. Kong, et al. Where is the hope for drug discovery? Let history tell the future. *Drug Discov Today* 2009;3–4:115–19. <http://dx.doi.org/10.1016/j.drudis.2008.07.002>
 4. Patwardhan B and Mashelkar AR. Traditional medicinal –inspired approaches to drug discovery: Can Ayurveda show the way forward! *Drug Discovery Today* 2009;14(15/16):804-11. <http://dx.doi.org/10.1016/j.drudis.2009.05.009>
 5. Randhawa KG, Kullar SJ, Rajkumar. Bioenhancer from mother nature and their applicability to modern medicines. *International Journal of applied and basic medicinal research* 2001;1(1):5-10.
 6. Kirtikar KR and Basu BD. *Indian Medicinal Plants*, 2nd Edn, Lalit Mohan Basu Publications, Allahabad, 1933:2131-33.
 7. Anonymous. *The wealth of India, raw materials*, vol VIII. Council of Scientific and Industrial Research, New Delhi, 1998:99–15.
 8. Bisht BS. Complete pharmacognosy of *Piper longum*. *Planta Med* 1963;11:410-13. <http://dx.doi.org/10.1055/s-0028-1100257>
 9. Evans WC. Trease and Evans' *Pharmacognosy*, 14th edn. W. B. Saunders, London, 1997:363–64.
 10. Atal N, Bedi KL. Bioenhancers: Revolutionary concept to market. *J-AIM* 2010;1(2)96-99.
 11. Qazi GN, et al. Council of Scientific and Industrial Research. Bioavailability / Bioefficacy Enhancing Activity of *Cuminum cyminum* and Extracts and Fractions Thereof. US Patent 52873;2004:Mar18.
 12. Johri RK, Zutshi U. An Ayurvedic formulation 'Trikatu' and its constituents. *J Ethnopharmacol* 1992;37:85-91. [http://dx.doi.org/10.1016/0378-8741\(92\)90067-2](http://dx.doi.org/10.1016/0378-8741(92)90067-2)
 13. Zutshi U, et al. A process for preparation of pharmaceutical combination with enhanced activity for treatment of tuberculosis and leprosy. Indian Patent No 1232/DEL89. Date of Publication 1989.
- Stecher PG. *The Merck index an encyclopedia of chemicals and drugs*. 7th ed. Rahway: Merck & Co. 1960:823.
- Merck Index, 11th Edition, 7442.

L. Rugheimer, Ber., 1882;15:1390.

<http://dx.doi.org/10.1002/cber.188201501298>

Raffaele Capasso, et al. Effect of piperine, the active ingredient of black pepper, on intestinal secretion in mice. *Life Sciences* 2002;71:2311–17.

18. Balsamo A, et al. Pecchia A. Structure activity relationship in cinnamamides, synthesis and pharmacological evaluation of some (E)- and (Z)-N-alkyl-, Pdimethyl cinnamamides. *J Med Chem* 1975;18:45-52. <http://dx.doi.org/10.1021/jm00242a018>

19. Balsamo A, et al. synthesis and pharmacological evaluation of some (E)- and (Z)-Nalkyl a, P-dimethyl cinnamamides substituted on the phenyl group. *J Med Chem* 1977;20:48-53.

<http://dx.doi.org/10.1021/jm00211a009>

20. The Merck Index, 10th ed.; pp 284–285, pp 1077–1078.

([http://www.erowid.org/archive/rhodium/chemistry/3base/pipe ron al.pepper/piperine/mi.piperine.txt](http://www.erowid.org/archive/rhodium/chemistry/3base/pipe%20ronal.pepper/piperine/mi.piperine.txt))

21. Majeed and Prakash L. The Chemical Constituents of Pepper, In *Pepper News*. 2000;25(1):123-31.

22. Tabuneng W, Bando H, Amiya T. Studies on the constituents of the crude drug Piper Longi Fructus. *Chem and Pharma Bull* 1983; 31(10):3562-65. <http://dx.doi.org/10.1248/cpb.31.3562>

23. Shankaracharya NB, Rao LJ, Naik JP, Nagalakshmi S. Characterization of chemical constituents of Indian Long Pepper. *J Food Sci Tech* 1997;34(1):73-75.

24. Pasto DJ, Johnson CR. *Organic Structure Determination*; Prentice Hall: Englewood Cliffs, NJ, 1969;109–57.

25. Bajad Sunil, Singla AK, Bedi KL. Liquid chromatography method for determination of piperine in rat plasma: application to pharmacokinetics. *J chromatogr B* 2002;776:245-49.

[http://dx.doi.org/10.1016/S1570-0232\(02\)00352-5](http://dx.doi.org/10.1016/S1570-0232(02)00352-5)

26. Suresh D and Srinivasan K. Tissue distribution and elimination of capsaicin, piperine and curcumin following oral intake in rats. *Indian J Med Res* 2010;131:682-91.

27. Bhat BG, Chandrasekhara N. Studies on the metabolism of piperine: Absorption, tissue distribution and excretion of urinary conjugates in rats. *Toxicology* 1986;40:83-92.

[http://dx.doi.org/10.1016/0300-483X\(86\)90048-X](http://dx.doi.org/10.1016/0300-483X(86)90048-X)

28. Bhat BG, Chandrasekhara N. Metabolic disposition of piperine in the rat. Metabolic disposition of piperine in the rat. *Toxicology* 1987;44(1):99-06.

[http://dx.doi.org/10.1016/0300-483X\(87\)90049-7](http://dx.doi.org/10.1016/0300-483X(87)90049-7)

29. Piyachaturwat P, Glinsukon T and Toxkulkao C. Acute and subacute toxicity in mice, rats and hamster. *Toxicology letters* 1983;6:351-359.

[http://dx.doi.org/10.1016/0378-4274\(83\)90198-4](http://dx.doi.org/10.1016/0378-4274(83)90198-4)

30. Khanuja SPS, et al. Composition comprising pharmaceutical/nutraceutical agent and a bioenhancer obtained from *Glycyrrhiza glabra*. Date of Publication: 27/12/2005. United States Patent Number, US006979471B1.
31. Atal CK, Zutshi U, Rao PG. Scientific evidence of the role of Ayurvedic herbals on bioavailability of drugs. *J Ethnopharm* 1981;4:229-33.
[http://dx.doi.org/10.1016/0378-8741\(81\)90037-4](http://dx.doi.org/10.1016/0378-8741(81)90037-4)
32. Atal CK, et al. Biochemical basis of enhanced drug availability by piperine: Evidence that piperine is a potent inhibitor of drug metabolism. *J Pharmacol Exptal Therap* 1985;232:258-62.
33. Reen RK, Roesch SF, Kiefer F, Weibel FJ, Singh, J. Piperine impairs cytochrome PA50 1A1 by direct interaction with the enzyme and not by down regulation of CYP1A1 gene expression in rat hepatoma 5 L Cell. Line. *Biochem. Biophys. Research Comm.* 1996;218:562-69.
<http://dx.doi.org/10.1006/bbrc.1996.0100>
34. Dubey K, et al. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. *Biochemical Pharmacology* 1993;46(2):229-38.
[http://dx.doi.org/10.1016/0006-2952\(93\)90408-O](http://dx.doi.org/10.1016/0006-2952(93)90408-O)
35. Annamalai AR, Manavalan R. Effects of Trikatu and its individual components and piperine on gastrointestinal tracts: Trikatu-a bioavailable enhancer. *Indian Drugs* 1990;27:595-04.
36. Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: Influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. *Phytomedicine* 2002;9:224–31. <http://dx.doi.org/10.1078/0944-7113-00114>
37. Khajuria A, Zutshi U, Bedi K L. Permeability characteristics of piperine on oral absorption--an active alkaloid from peppers and a bioavailability enhancer. *Indian J Exp Biol* 1998;36(1):46-50.
38. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients. *Phytother Res* 2009;23(9):1281-86. <http://dx.doi.org/10.1002/ptr.2676>
39. Jin MJ, Han HK. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. *J Food Sci* 2010;75(3):H93-96. <http://dx.doi.org/10.1111/j.1750-3841.2010.01542.x>
40. Janakiraman K and Manavalan R. Compatibility and stability studies of ampicillin trihydrate and piperine mixture. *IJPSR*, 2011;2(5):1176-81.
41. Shoba G, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 1998;64(4):353-56. <http://dx.doi.org/10.1055/s-2006-957450>
42. Kasibhatta R, Naidu MU. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. *Drugs R D* 2007;8(6):383-91.
<http://dx.doi.org/10.2165/00126839-200708060-00006>

43. Singh A, et al. In - Vivo Assessment of Enhanced Bioavailability of Metronidazole with Piperine in Rabbits. RJPBCS 2010;1(4):273-278.

44. Pooja S. Analgesic activity of Piper Nigrum extract per se and its interaction with diclofenac sodium and pentazocine in albino mice. The Internet Journal of Pharmacology 2007;5(1)30.

45. Badmaev V, Majeed M, Prakash L. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation. J Nutr Biochem 2000;11:109–13.

[http://dx.doi.org/10.1016/S0955-2863\(99\)00074-1](http://dx.doi.org/10.1016/S0955-2863(99)00074-1)

46. Badmaev V, Majeed M, Norkus PE. Piperine, an alkaloid derived from black pepper increases serum response of beta-carotene during 14-days of oral beta-carotene supplementation. Nutrition Research 1999;19(3):381-88.

[http://dx.doi.org/10.1016/S0271-5317\(99\)00007-X](http://dx.doi.org/10.1016/S0271-5317(99)00007-X)

47. Veda S, Srinivasan K. Influence of dietary spices – Black pepper, red pepper and ginger on the uptake of β -carotene by rat intestines. Journal of Functional Foods 2009;1(4):394-98.

<http://dx.doi.org/10.1016/j.jff.2009.10.002> 48. Boddupalli MB, Anisetti NR, Ramani R, Malothu N. Enhanced pharmacokinetics of omeprazole when formulated as gastroretentive microspheres along with piperine. Asian Pac J Trop Dis 2014; 4(Suppl 1): S129-33.

[http://dx.doi.org/10.1016/S2222-1808\(14\)60427-8](http://dx.doi.org/10.1016/S2222-1808(14)60427-8)

49. Desai SK, Gawali VS, Naik AB, D'souza LL. Potentiating Effect of Piperine on Hepatoprotective Activity of Boerhavia diffusa to Combat Oxidative Stress. International Journal Of Pharmacology 2008;4(5):393-97. <http://dx.doi.org/10.3923/ijp.2008.393.397>

50. Bano G et al, Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. European Journal of Pharmacology 1991;41(6):615-17. <http://dx.doi.org/10.1007/BF00314996>

51. Johnson JJ et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Molecular Nutrition & Food Research 2011;55:1169–76. <http://dx.doi.org/10.1002/mnfr.201100117>

52. Janakiraman K, Manavalan R. Studies on effect of piperine on oral bioavailability of ampicillin and norfloxacin. Afr J Trad Med 2008;5(3):257– 62.

53. Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian journal of experimental biology 2002;40(3):277-81.

54. Lambert DJ, Hong J, Kim HD, Mishin MV, Yang SC. Piperine Enhances the Bioavailability of the Tea Polyphenol-Epigallocatechin-3-gallate in Mice. J Nutr 2004;134:1948–52.

55. Khan AI, Mirza MZ, Kumar A, Verma V, Qazi NG. Piperine, a Phytochemical Potentiator of Ciprofloxacin against Staphylococcus aureus. Antimicrobial agents and chemotherapy 2006;50(2):810–

56. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of Piperine on the Steady-state Pharmacokinetics of Phenytoin in Patients with Epilepsy. Phytother Res 2006;20:683–86.

<http://dx.doi.org/10.1002/ptr.1937>

57. Gupta SK, Velpandian T, Sengupta S, Mathur P, Sapra P. Influence of Piperine on Nimesulide Induced Antinociception. *Phytotherapy Research* 1998;12:266–69.
58. Mujumdar AM, et al. Effect of piperine on bioavailability of pentobarbitone induced hypnosis in rats. *Indian Journal of Experimental Biology* 1990;28:486-87.
59. Patel S, et al. Influence of co-administration of piperine on pharmacokinetic profile of gatifloxacin in layer birds. *Global Veterinaria* 2011;7:427-32.
60. Devada SS, et al. Bioenhancing activity of piperine on pharmacokinetics of gatifloxacin in broiler birds. *Inventi Impact: Planta Activa* 2011;Inventi:ppa/10/11.
61. Singh A, Chand S. Improved bioavailability of atenolol with piperine in rats. *International Journal of Pharmaceutical Research* 2011;3:88-91.
62. Singh A, et al. Enhanced bioavailability of losartan potassium with piperine in rats. *International Journal of Pharmacy Research and Technology* 2012;2:34-36.
63. Bhardwaj KR, et al. Piperine, a Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4. *JPET* 2002;302(2):645–50.
<http://dx.doi.org/10.1124/jpet.102.034728>
64. Venkatesh S, Durga KD, Padmavathi Y, Reddy BM, Mullangi R. Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics. *Drug Research* 2011;61:506-09.
65. Chawla PC. Resorine: A novel CSIR drug curtails TB treatment. *CSIR news* 2010;60:52-54
66. Kesarwani, K., & Gupta, R. (2013). Bioavailability enhancers of herbal origin: An overview. *Asian Pacific Journal of Tropical Biomedicine*, 3(4), 253–266.

DigesSEB

1. <http://www.specialtyenzymes.com>
2. "Amylase, Alpha", I.U.B.: 3.2.1.11, 4- α -D-Glucan glucanohydrolase.
3. "Effects of pH (Introduction to Enzymes)". [worthington-biochem.com](http://www.worthington-biochem.com). Retrieved 17 May 2015.
4. Ramasubbu, N.; Paloth, V.; Luo, Y.; Brayer, G. D.; Levine, M. J. (1996). "Structure of Human Salivary α -Amylase at 1.6 Å Resolution: Implications for its Role in the Oral Cavity". *Acta Crystallographica Section D*. 52 (3): 435–446. PMID 15299664. doi:10.1107/S0907444995014119.
5. Rejzek, M.; Stevenson, C. E.; Southard, A. M.; Stanley, D.; Denyer, K.; Smith, A. M.; Naldrett, M. J.; Lawson, D. M.; Field, R. A. (2011). "Chemical genetics and cereal starch metabolism: Structural basis of the non-covalent and covalent inhibition of barley β -amylase". *Molecular BioSystems*. 7 (3): 718–730. PMID 21085740. doi:10.1039/c0mb00204f.
6. Robert Hill and Joseph Needham, *The Chemistry of Life: Eight Lectures on the History of Biochemistry* (London, England: Cambridge University Press, 1970), page 17 ; (2) Richard B. Silverman, *The Organic Chemistry of Enzyme-catalyzed Reactions*, 2nd ed. (London, England: Academic Press, 2002), page 1 ; (3) Jochanan Stenesh, *Biochemistry*, vol. 2 (New York, New York: Plenum, 1998), page 83 ; (4) Robert A. Meyers, ed., *Molecular Biology and Biotechnology: A Comprehensive Desk Reference* (New York, New York: Wiley-VCH, 1995), page 296.

Omnilean

1. Omniactives.com
2. Alam AM, Ahuja A, Baboota S, Gidwani SK, Ali J. Formulation and evaluation of Pharmaceutically equivalent parental depot suspension of methyl prednisolone acetate. *Indian J Pharm Sci.* 2009;71:30–3.
3. Allian CC, Poon LS, Chan CS, Richmond W, Paul CF. Enzymatic determination of total serum cholesterol. *Clin Chem.* 1974;20:470–5.
4. Andrade-Cetto, A., & Heinrich, M. (2005). Mexican plants with hypoglycaemic effect used in the treatment of diabetes. *Journal of Ethnopharmacology*, 99(3), 325-348.
5. Ansarullah, Jadeja RN, Thounaojam MC, Patel V, Devkar RV, Ramachandran AV. Antihyperlipidemic potential of a polyherbal preparation on triton WR 1339 (Tyloxapol) induced hyperlipidemia: A comparison with lovastatin. *Int J Green Pharm.* 2009;3:119–24.
6. Blois, M. S. (1958). Antioxidant determinations by the use of a stable free radical.
7. Braga Filho, J. R., Veloso, V. R. S., Naves, R. V., Ferreira, G. A.. Entomofauna associada aos frutos do bacupari, *Salacia crassifolia* (MART.) Peyr, nos cerrados do Brasil Central. *Pesq. Agropec. Trop.*, 31 (1), p. 47-54, 2001.
8. Chang, C. C., Yang, M. H., Wen, H. M., & Chern, J. C. (2002). Estimation of total flavonoid content in propolis by two complementary colorimetric methods. *Journal of food and drug analysis*, 10(3).
9. Chavan, J. J., Jagtap, U. B., Gaikwad, N. B., Dixit, G. B., & Bapat, V. A. (2013). Total phenolics, flavonoids and antioxidant activity of Saptarangi (*Salaciachinensis* L.) fruit pulp. *Journal of plant biochemistry and biotechnology*, 22(4), 409-413.
10. Dassanayake, M. D. Clayton WD (ed.). 1996 A revised handbook to the flora of Ceylon: volume X. Rotterdam: Balkema 426p.-. ISBN, 464168091.
11. Deepak, K. G. K., Neelapu, N. R. R., & Challa, S. (2014). Role of Antidiabetic Compounds on Glucose Metabolism A Special Focus on Medicinal Plant: *Salacia* sps. *Medicinal Chemistry*, 2014.
12. Dhanabalasingham, B., Karunaratne, V. Tezuka, Y., Kikuchi, T. Gunatilaka, A. A. L.. Biogenetically important quinonemethides and other triterpenoid constituents of *Salacia reticulata*. *Phytochemistry*, 42 (5), p. 1377-1385, 1996.
13. Dharmadasa, R. M., Hettiarachchi, P. L., & Premakumara, G. A. S. (2014). Anatomical Traits as an Additional Taxonomic Tool for *Munroniapinnata* (Wall.) Theob.(Meliaceae) Found in Sri Lanka. *World Journal of Agricultural Research*, 2(4), 142-150.
14. Dharmadasa, R. M., Premakumara, G. A. S., Hettiarachi, P. L., & Ratnasooriya, W. D. (2012). Cytotoxicity and in vivo antimalarial activity of aqueous whole plant extract of *Munroniapinnata* (Wall.) Theob.(Meliaceae) in mice. *Res J Med Plant*, 6, 267-273.
15. Dharmadasa, R. M., Samarasinghe, K., Adhihetty, P., & Hettiarachchi, P. L. (2013). Comparative Pharmacognostic Evaluation of *Munroniapinnata* (Wall.) Theob.(Meliaceae) and Its Substitute *Andrographis paniculata* (Burm. f.) Wall. Ex Nees (Acanthaceae). *World journal of agricultural research*, 1(5), 77-81.
16. Dharmadasa, R. M., Siriwardana, A., Samarasinghe, K., & Adhihetty, P. (2013). Standardization of *Gyrinops Walla Gaertn.*(Thymalaeaceae): Newly Discovered, Fragrant Industrial Potential, Endemic Plant from Sri Lanka. *World Journal of Agricultural Research*, 1(6), 101-103.
17. Farnsworth, N. R. (1966). Biological and phytochemical screening of plants. *Journal of pharmaceutical Sciences*, 55(3), 225-276.

18. Friedman M, Byers SO. Mechanism underlying hypercholesterolemia induced by triton WR-1339. *Am J Physiol.* 1957;190:439–45.
19. Gami, B., & Parabia, M. H. (2010). Pharmacognostic evaluation of bark and seeds of *Mimusops elengi* L. *Int J Pharm PharmSci*, 2(Suppl 4), 110-3.
20. Ghule BV, Ghante MH, Saoji AN, Yeole PG. Hypolipidemic and antihyperlipidemic effects of *Lagenariasiceraria* (Mol.) fruit extracts. *Indian J Exp Biol.* 2006;44:905–9.
21. Gong, Y., Hou, Z., Gao, Y., Xue, Y., Liu, X., & Liu, G. (2012). Optimization of extraction parameters of bioactive components from defatted marigold (*Tagetes erecta* L.) residue using response surface methodology. *Food and Bioproducts Processing*, 90(1), 9-16.
22. Gopalakrishnan S, Ismail ST, Begum HV, Elango V. Anti-inflammatory activity of *Salaciaoblunga* Wall. And *Azimatetracantha* Lam. *J Ethnopharmacol.* 1997;56:145–52.
23. Grover, J. K., Vats, V., Rath, S. S., & Dawar, R. (2001). Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. *Journal of Ethnopharmacology*, 76(3), 233-238.
24. Halliwell, B., & Gutteridge, J. M. (1990). The antioxidants of human extracellular fluids. *Archives of biochemistry and biophysics*, 280(1), 1-8.
25. Harwig, J., & Scott, P. M. (1971). Brine shrimp (*Artemiasalina* L.) larvae as a screening system for fungal toxins. *Applied microbiology*, 21(6), 1011-1016.
26. Im, R., Mano, H., Matsuura, T., Nakatani, S., Shimizu, J., & Wada, M. (2009). Mechanisms of blood glucose-lowering effect of aqueous extract from stems of *Kothalahimbutu* (*Salaciareticulata*) in the mouse. *Journal of ethnopharmacology*, 121(2), 234-240.
27. India: Ministry of Social Justice and Empowerment; 2000. Committee for the Purpose of Control and Supervision of Experimental Animals (CPCSEA), OECD Guidelines for the testing of chemicals, revised draft guidelines 423: Acute Oral toxicity- Acute toxic class method, revised document.
28. Inman WD, Reed MJ. In-ventors; Shaman Pharmaceuticals, assignee Triterpenoid compound for the treatment of diabetes. US Patent 5, 691, 386. 1997 Nov 25;
29. Jansakul C, Jusapalo N, Mahattanadul S. Hypotensive effect of n-butanol extract from stem of *Salacia chinensis* in rats, *ISHS Acta Horticulturae* 678: III WOCMAP Congress on Medicinal and Aromatic Plants. Targeted Screening of Medicinal and Aromatic Plants, Economics and Law. Vol. 4
30. Jihong, Y.; Shaozhong, L.; Jingfeng, S.; Kobayashi, M.; Akaki, J.; Yamashita, K.; Tamesada, M.; Umemura, T.. Effects of *Salacia chinensis* extract on reproductive outcome in rats. *Food Chem. Toxicol.*, 49, p. 57-60, 2011.
31. Khandewal KR. 14th ed. Pune, India: Nirali Prakashan; 2005. Practical Pharmacognosy; pp. 146–
32. Kishino, E., Ito, T., Fujita, K., & Kiuchi, Y. (2006). A mixture of the *Salaciareticulata* (*Kotalahimbutu*) aqueous extract and cyclodextrin reduces the accumulation of visceral fat mass in mice and rats with high-fat diet-induced obesity. *The Journal of Nutrition*, 136(2), 433-439.
33. Lucy Dey, Anoja S. Attele, Chun-Su Yuan. 2002. Alternative therapies for type 2 diabetes. *Alternative Medicine Review*, 45-57
34. Luxmini. K.P.A.M.K, Dharmadasa. R.M, Samarasinghe, K. Muthukumarana. P.R.M. 2015. Comparative. Comparative Pharmacognostic Study of Different Parts of *Withaniasomnifera* and its Substitute *Ruelliatuberosa*. *World Journal of Agricultural Research*, 3(1), 28-33.
35. Michael, A. S., Thompson, C. G., & Abramovitz, M. (1956). *Artemiasalina* as a Test Organism for Bioassay. *Science*, (123), 464.
36. Ministry of Health (India) (948). Pharmacopoeia of India. Government of India. 1982:650.

37. Morikawa, T., Akaki, J., Ninomiya, K., Kinouchi, E., Tanabe, G., Pongpiriyadacha, Y., & Muraoka, O. (2015). Salacinol and Related Analogs: New Leads for Type 2 Diabetes Therapeutic Candidates from the Thai Traditional Natural Medicine *Salaciachinensis*. *Nutrients*, 7(3), 1480-1493.
38. Naveen A. Hepatoprotective activity of ethanolic extract of root bark of *Salacia chinensis*. *J Pharm Res.* 2010;3:833–4.
39. Nobori, T. (1994). Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. *Trends in Genetics*, 10(7), 228.
40. Nomura H, Kimura Y, Okamoto O, Shiraishi G. Effects of antihyperlipidemic drugs and diet plus exercise therapy in the treatment of patients with moderate Hypercholesterolemia. *Clin Ther.* 1996;18:196.
41. Panda, A., Jena, S., Sahu, P. K., Nayak, S., & Padhi, P. (2013). Effect of Poly herbal Mixtures on the Treatment of Diabetes. *ISRN endocrinology*, 2013.
42. Pande VV, Dubey S. Antihyperlipidemic activity of *Sphaeranthus indicus* on atherogenic diet induced hyperlipidemia in rats. *Int J Green Pharm.* 2009;3:159–61.
43. Pelka, M., Danzl, C., Distler, W., & Petschelt, A. (2000). A new screening test for toxicity testing of dental materials. *Journal of dentistry*, 28(5), 341-345.
44. Phipps, J. A., Wilkinson-Berka, J. L., & Fletcher, E. L. (2007). Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. *Investigative Ophthalmology and Visual Science*, 48(2), 927.
45. Saravana K, Mazumder A, Saravanan VS. Antihyperlipidemic activity of *Camellia sinensis* leaves in Triton WR-1339 induced albino rats. *Pharmacogn Mag.* 2008;4:60–4.
46. Sellamuthu PS, Muniappan BP, Perumal SM, Kandasamy M. Antihyperglycemic effect of mangiferin in streptozotocin induced diabetic rats. *J Health Sci.* 2009;55:206–14.
47. Sharanabasappa, G. K., Santosh, M. K., Shaila, D., Seetharam, Y. N., & Sanjeevarao, I. (2007). Phytochemical Studies on *Bauhinia racemosa* Lam. *Bauhinia purpurea* Linn. and *Hardwickia binata* Roxb. *Journal of Chemistry*, 4(1), 21-31.
48. Shi, H., Sui, Y., Wang, X., Luo, Y., & Ji, L. (2005). Hydroxyl radical production and oxidative damage induced by cadmium and naphthalene in liver of *Carassius auratus*. *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology*, 140(1), 115-121.
49. Shimada, K., Fujikawa, K., Yahara, T., Nakamura (1992) Antioxidative properties of xanthone on the auto oxidation of soybean in cyclodextrin emulsion *J. Agr. Food Chem.*, 40, 945-948.
50. Shimada, T., Nagai, E., Harasawa, Y., Watanabe, M., Negishi, K., Akase, T., & Aburada, M. (2011). *Salaciareticulata* inhibits differentiation of 3T3-L1 adipocytes. *Journal of Ethnopharmacology*, 136(1), 67-74.
51. Siddhuraju, P., & Becker, K. (2007). The antioxidant and free radical scavenging activities of processed cowpea (*Vigna unguiculata* (L.) Walp.) seed extracts. *Food Chemistry*, 101(1), 10-19.
52. Suhartono, E., Viani, E., Rahmadhan, M. A., Gultom, I. S., Rakhman, M. F., & Indrawardhana, D. (2012). Total flavonoid and antioxidant activity of some selected medicinal plants in South Kalimantan of Indonesian. *APCBEE Procedia*, 4, 235-239.
53. Svickova, M., Havranek, E., & Novak, V. (1993). [Determination of heavy metals in samples of herbal drugs using differential pulse polarography]. *Ceskoslovenskafarmacie*, 42(2), 68-70.
54. Tachakittirungrod, S., Okonogi, S., & Chowwanapoonpohn, S. (2007). Study on antioxidant activity of certain plants in Thailand: Mechanism of antioxidant action of guava leaf extract. *Food Chemistry*, 103(2), 381-388.

55. Tran, T. M.; Nguyen, T. H. A.; Vu, D. T.; Tran, V. S. Study on chemical constituents and cytotoxic activities of *Salacia chinensis* growing in Vietnam. *J. Chem. Sci.*, 65 (10), p. 1284-1288, 2010.
56. Vivas, L., Easton, A., Kendrick, H., Cameron, A., Lavandera, J. L., Barros, D., & Croft, S. L. (2005). *Plasmodium falciparum*: stage specific effects of a selective inhibitor of lactate dehydrogenase. *Experimental parasitology*, 111(2), 105-114.
57. Wagner, H., Bladt, S., 2001. *Phytochemical screening* Plant Drug Analysis. A Thin Layer Chromatography Atlas, second ed. Springer, Berlin.
58. Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004). Global prevalence of diabetes estimates for the year 2000 and projections for 2030. *Diabetes care*, 27(5), 1047-1053.
59. World Health Organization. (1998). Quality control methods for medicinal plant materials.
60. Yadav, R. N. S., & Agarwala, M. (2011). Phytochemical analysis of some medicinal plants. *Journal of Phytology*, 3(12).
61. Yoshikawa M, Zhang Y, Wang T, Nakamura S, Matsuda H. New triterpene constituents, foliasalacins A₁-A₄, B₁-B₃, and C, from the leaves of *Salacia chinensis*. *Chem Pharm Bull (Tokyo)* 2008;56:915-20.
62. Yoshino, K., Kanetaka, T., & Koga, K. (2014). Antioxidant Activity of *Salacia* Plant (*Salacia reticulata*). *Shokuhin eiseigakkaishi. Journal of the Food Hygienic Society of Japan*, 56(4), 144-150.
63. Zandberg, W. F.; Mohan, S.; Kumarasamy, J.; Mario Pinto, B. Capillary zone electrophoresis method for the separation of glucosidase inhibitors in extracts of *Salacia reticulata*, a plant used in Ayurvedic treatments of type-2 diabetes. *Anal. Chem.*, 82, p. 5323-5330, 2010.

